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We compared 30-day case-fatality rates for patients infected with Clostridium difficile possessing genes 
for toxins A and B without binary toxin (n = 212) with rates for patients infected with C. difficile possessing 
genes for A, B, and binary toxin. The latter group comprised patients infected with strains of PCR ribotype 
027 (CD027, n = 193) or non-027 (CD non-027, n = 72). Patients with binary toxin had higher case-fatality 
rates than patients without binary toxin, in univariate analysis (relative risk [RR] 1.8, 95% confidence 
interval [CI] 1.2–2.7) and multivariate analysis after adjustment for age, sex, and geographic region (RR 
1.6, 95% CI 1.0–2.4). Similar case-fatality rates (27.8%, 28.0%) were observed for patients infected with 
CD027 or CD non-027. Binary toxin either is a marker for more virulent C. difficile strains or contributes 
directly to strain virulence. Efforts to control C. difficile infection should target all virulent strains 
irrespective of PCR ribotype.   
Clostridium difficile infection (CDI) is a common cause of health care–associated 
diarrhea in industrialized countries (1), and the leading cause of intestinal infection related to 
antimicrobial drug consumption (2). Clinical manifestations range from mild to severe diarrhea, 
pseudomembranous colitis, toxic megacolon, sepsis, and ultimately death. Risk factors for CDI 
include duration of hospital stay, underlying illness, age (3), and previous use of virtually any 
antimicrobial drug, most frequently cephalosporins and fluoroquinolones (4–10). 
The hypervirulent fluoroquinolone-resistant C. difficile PCR ribotype 027 North 
American pulsed-field type 1 (NAP1) (REA type BI, toxinotype III) has received attention as the 
cause of increasingly severe outbreaks and higher death rates, longer hospital stays, and frequent Page 2 of 15 
relapses (8,9,11,12). However, whether it really causes increased severity is questionable. 
Characteristics observed by previous studies may be due to selection bias or to the procedures 
used for diagnostic testing and reporting of cases; disease severity was similar in 2 groups of 
patients (PCR ribotype 027 and non-027) when recruitment to the study was done without 
reference to clinical signs and symptoms or PCR ribotype (13). 
The pathogenicity of C. difficile is based on the action of at least 1 of the 2 main 
cytotoxins (A and B) acting as glycosyltransferases that modify guanose triphosphatases within 
the intestinal epithelial cells and lead to the disruption of the actin cytoskeleton. A recent study, 
which used a gene knock-out system, reinforced the fact that toxins A and B are comparable in 
terms of virulence, as shown by in vitro cytotoxicity and virulence in vivo (14). A binary toxin 
C. difficile transferase is found in some strains and belongs to the actin-modifying adenide 
dinucleotide protein–ribosyltransferases, which also impair the structure of actin cytoskeleton in 
epithelial cells (15,16). The pathologic significance of binary toxin is not yet clear. However, a 
recent study reports that binary toxin not only affects the actin cytoskeleton but also induces the 
formation of microtubule-based protrusions on the surface of epithelial cells, leading to increased 
adherence (17). 
Cultures positive for C. difficile are notifiable by the diagnostic laboratories in Denmark 
as part of the surveillance for gastrointestinal infections; in addition, isolates are selected under 
certain criteria and submitted to the National Reference Laboratory at Statens Serum Institut for 
further typing. The aim of the present study was to determine the case-fatality rate after diagnosis 
with C. difficile, according to toxin profile and PCR ribotype. 
Methods 
Surveillance System and Registries 
All entries to 3 national registries in Denmark (the Danish Civil Registration System, the 
national Registry of Enteric Pathogens, and the C. difficile Microbiological Database) use a 
unique person registration number. These identifiers were used for the study. The study was 
retrospective, and we used a cohort design in which 4 groups of case-patients with C. difficile 
infection (Figure 1) were monitored from the date of diagnosis until the date of death or date of 
extraction from the registry. The study was conducted during week 1 of 2008 through week 22 of Page 3 of 15 
2009. The unique patient identifier was used to link the registries. None of the registries contain 
clinical data. 
The Danish Civil Registration System contains demographic information on all residents 
of Denmark and was used to retrieve the date of death. This registry does not contain information 
on the cause of death. The national Registry of Enteric Pathogens includes weekly case-based 
notifications of cultures positive for C. difficile from all departments of clinical microbiology of 
regional hospitals in the country. A second case-based database, the C. difficile Microbiological 
Database, which is separate from the Registry of Enteric Pathogens, contains information on 
isolates that undergo genotypic toxin detection and PCR ribotyping at the National Reference 
Laboratory at Statens Serum Institut, Copenhagen. Isolates are forwarded by departments of 
clinical microbiology if they are resistant to moxifloxacin, if severe clinical course is observed, 
or if an outbreak is suspected. These criteria were established in 2007, when sporadic cases of C. 
difficile PCR ribotype 027 were found for the first time in Denmark (7). They were reinforced in 
2009, when the country experienced the first large C. difficile PCR ribotype 027 outbreak, which 
involved different hospitals of the Copenhagen Capital Region (18). Information on which 
specific criteria were used for submission of the individual isolates for subtyping was not 
available. No laboratory standard for primary diagnostics of CDI has been developed at the 
national level, and clinical microbiology departments use different methods, including 
environmental impact assessment, culture, PCR, or standard cytotoxin assays. 
All isolates referred to Statens Serum Institut are genotyped to detect genes for the 3 
toxins (A and B, and binary toxin). PCR ribotyping is subsequently performed on isolates 
possessing the genes for all 3 toxins (Figure 1). The methods used for genotyping of toxins and 
PCR ribotyping have been described in detail elsewhere (19,20). This study was approved by the 
Danish Data Protection Board. 
Definitions 
Patients were assigned to 4 groups, depending on the characteristics of the isolates 
(Figure 1). Infected patients with an isolate possessing genes for toxins A and B and binary toxin 
were categorized either as C. difficile PCR ribotype 027 (CD027) or C. difficile PCR ribotype 
non-027 (CD non-027). A third group included patients infected with a strain possessing genes 
encoding for toxins A and toxin B, but not the binary toxin genes (CD A and B). A fourth group Page 4 of 15 
was created by subtracting the other 3 groups from patients with C. difficile infection that were 
notified to the surveillance laboratory system. Therefore, such patients were infected with 
isolates not referred for typing, presumably because the criteria for submission were not fulfilled. 
We refer to this group as unselected C. difficile unselected (CD-unselected).The distribution of 
the different PCR ribotypes in the group CD non-027 was described. 
Only the first episode of infection of the patient was considered. The first episode of 
CD027 overruled the first episode of CD non-027; the first episode of CD non-027 overruled the 
first episode of CD A and B; and the first episode of CD A and B overruled the first episode of 
unselected C. difficile infection. Therefore, the final dataset included only 1 observation per 
patient. The date on which the stool sample was collected was defined as the date of diagnosis. 
Statistical Methods 
Kaplan Meier survival curves were created to determine the effect of time after diagnosis 
on the risk for death. Differences between curves were compared by using the log-rank test. 
Multivariate Poisson regression was used to estimate the risk ratio of death within 30 days after 
diagnosis. For survival analysis, patients were categorized into 2 groups, according to the 
presence or absence of binary toxin. Analysis was performed with STATA version 10 
(StataCorp, College Station, TX, USA). Case-patients for whom 30 days of follow-up after 
infection could not be completed were excluded from the analysis (163 cases). 
Results 
After the 2 microbiological datasets were merged, 2,299 case-patients with a first episode 
of infection were identified for the 17-month study. Of the 2,299 case-patients, isolates from 477 
were referred to the national laboratory and were genotyped for toxins; of these 265 had genes 
for toxin A, toxin B, and binary toxin and were further ribotyped by PCR. Therefore, the 4 
groups of patients with C. difficile infection used for the study consisted of 1,822 CD unselected, 
212 CD A and B, 193 CD027, and 72 CD non-027. None of the isolates were positive for genes 
encoding only toxin A or B. The group of 72 CD non-027 consisted of 24 C. difficile PCR 
ribotype 078 (33%), 26 C. difficile PCR ribotype 66 (36%), and 22 C. difficile PCR ribotype 23, 
together with 9 other PCR ribotypes (31%). Page 5 of 15 
Gender was equally distributed among the 4 groups of patients with CD unselected, CD 
027, CD non-027, and CD A and B. The proportion of case-patients <50 years of age was much 
higher in the group with CD unselected (27.1%), compared with that of groups CD027 (4.6%) 
and CD non-027 (9.7%), which had more case-patients >80 years of age (Table 1). Most of the 
CD unselected, CD A and B, and CD non-027 were submitted by local clinical microbiology 
laboratories from areas not including the Capital region; most CD027 occurred in the Capital 
region, where the outbreaks of CD027 occurred in 2008–2009 (Table 1). 
The case-fatality rate in patients 30 days after diagnosis (28%) was independent of PCR 
ribotype in patients infected with strains that were positive for the binary toxin. More 
specifically, 54/193 case-patients with CD027 (28.0%, 95% confidence interval [CI] 21.8–34.9), 
and 20/72 case-patients with CD non-027 (27.8%, 95% CI 17.9–39.6) died within 30 days after 
infection. Case-fatality rate was 17.0% (36/212) for the group infected with CD A and B (95% 
CI 12.2–22.7) that did not possess genes for binary toxin, and lower (13.6%) for the 247/1,822 
case-patients infected with CD unselected (95% CI 12.0–15.2). Among patients with CD non-
027, seven deaths (29.2%) in CD078 were reported, 8 deaths (30.8%) in CD066, and 5 deaths in 
the group of other PCR ribotypes. No statistically significant difference was found between these 
case-fatality rates. 
Kaplan Meier curves were created for 1 year after diagnosis. A steep increase was seen in 
the case-fatality rates within 30 days after the diagnosis for all groups of patients, but especially 
evident for the 2 groups possessing the binary toxin genes (Figure 2). The shape of the curve for 
case-patients with binary toxin genes (CD027 and CD non-027) almost overlapped in the first 30 
days; curves for the other 2 groups had a different shape (log-rank test, p<0.001). The curve of 
the group of patients infected with CD A and B showed an intermediate case-fatality rate as 
compared with the 2 groups with binary toxin and CD unselected. The cumulative risk of death 
(Kaplan Meier function) after 60 days was 18.4% in case-patients with CD unselected 
(336/1,822), 24.5% in those with CD A and B infection (52/212), 37.1 % with CD027 (71/193), 
and 30.5% with CD non-027 (22/72). After 90 days, the cumulative risk of death rose to 20.9% 
for CD unselected (381/1,822), 26.8% for CD A and B (57/212), 38.9% for CD027 (75/193), and 
36.1% for CD non-027 (26/72). Kaplan Meier curves were also created after excluding all case-
patients <50 years of age for all 4 groups (550 case-patients) because of the higher proportion of 
patients <50 years of age in the group of CD unselected strains. The curves showed a similar Page 6 of 15 
shape as compared when using the full dataset (figure not shown, log rank test, p<0.001). The 
cumulative case-fatality rate at 30 days also remained comparable: 18.1% for case-patients with 
CD unselected strains (239/1,319), 19.8% for CD A and B (36/182), 29.0% for CD027 (53/183), 
and 29.2% for CD non-027 (19/65). 
On the basis of these observations, which showed a similar case-fatality pattern for the 
groups that possessed the genes for the binary toxin, in the regression analysis, we combined 
these 2 groups with the genes for the binary toxin (CD027 and CD non-027) into 1 group, and 
compared it with the group not possessing the binary toxin (CD A and B). Therefore, in the 
regression analysis, the group of CD unselected isolates was excluded because these isolates 
were not submitted for characterization. 
Univariate analysis showed that the relative risk (RR) for death within 30 days after 
diagnosis was (RR 1.8, 95% CI 1.2–2.7) for case-patients infected with C. difficile that possesses 
the genes for binary toxin in addition to toxin A and B, as compared with those infected with 
strains possessing only genes for toxin A and B, which provided the reference level (Table 2). 
Multivariate analysis, after adjustment for age, sex, and region, showed that the relative risk 
became 1.6 (95% CI 1.0–2.4) for case-patients infected with the strains encoding the genes for 
the binary toxin when compared with the reference group of patients infected with strains 
without the genes for binary toxin (Table 2). 
Discussion 
We used surveillance data to describe the case-fatality rate after a diagnosis of C. difficile 
infection. We found that the case-fatality rate is highest after infection with strains that possess 
genes for the binary toxin in addition to toxins A and B, irrespective of the PCR ribotype. Strains 
encoding genes for toxins A and B, but not binary toxin, showed a lower case-fatality risk. 
A number of studies have addressed the issue of risk for death and severity of disease 
after infection with C. difficile. Overall, C. difficile PCR ribotype 027 has been associated with 
more severe disease and increased death rates. Nevertheless, many studies did not have a strict 
sampling frame or appropriate epidemiologic design, and their findings have been questioned by 
recent evidence (13,21). Our results are consistent with the initial findings that C. difficile PCR 
ribotype 027 is associated with elevated risk of death, but we elaborate further on the molecular Page 7 of 15 
characterization according to toxin profile. We suggest that the previously observed high case-
fatality rate observed in C. difficile infection cannot be solely ascribed to excess risk for death 
after infection with PCR ribotype 027; other markers of virulence may be more appropriate than 
the PCR ribotype itself. The inclusion of case-patients on the basis of clinical findings only 
(1,8,9,12), the different criteria used to select strains for PCR ribotyping (13,21–23), or the lack 
of differentiation in separate groups according to toxin profiles (24) might have accounted for 
variation of estimates across the studies, as well as an overestimation of the risk for death 
associated with C. difficile PCR ribotype 027. 
We observed a 28% case-fatality rate at 30 days for the 2 groups possessing the binary 
toxin: estimates from previous studies in Canada indicated a risk for death of 23% for patients 
with C. difficile–associated disease (CDAD), in a hospital in which C. difficile PCR ribotype 027 
strain made up two-thirds of the isolates (12); or of 25% in another study involving 12 hospitals 
in which case-patients with CDAD were compared with controls without CDAD. In the latter 
study, 129/157 strains examined had pulsed-field gel electrophoresis patterns identical to NAP1 
(8). In the Netherlands, 12.9% lethality was reported for C. difficile PCR ribotype 027 as 
compared with 7.0% in other C. difficile PCR ribotypes non-027 (21). 
A few clinical studies indicate that the production of binary toxin correlates with the 
severity of CDI, rendering the strains with binary toxin more virulent. A case–control study 
conducted in 2005 included 26 patients infected with strains producing binary toxin in addition 
to toxins A and B and 42 controls infected with strains producing toxins A and B only. Diarrhea 
in case-patients was more frequently associated with abdominal pain (61.5% vs. 26.2%; p = 
0.003) and with liquid stools (76.9% vs. 59.5%; p = 0.14) (25). Another case–case study from 
2007 confirmed this tendency, showing that binary toxin–positive strains were significantly 
associated with more severe CDI (RR 3.38, 95% CI 1.29–8.85) and with higher case-fatality 
rates (RR 2.55, 95% CI 1.25–5.21) (26). Binary toxin–positive strains that produced neither 
toxins A and B were investigated in the rabbit ileal loop model to elucidate the contribution of 
binary toxin in the pathogenesis of CDI (27). This study showed that binary toxin contributed to 
marked nonhemorrhagic fluid responses when responses of nontoxigenic strains were compared. 
However, strains that produced toxins A and B gave rise to hemorrhagic fluid responses in this 
assay. In the same study, challenge with clindamycin-treated hamsters resulted in colonization of 
the binary toxin–positive strains but not diarrhea and death as seen for the strains that produced Page 8 of 15 
toxins A and B. Therefore, binary toxin may play an adjunctive role in the pathogenesis of 
disease caused by strains positive for toxins A and B (27). 
Historically, C. difficile infection was not considered a severe disease, and studies 
performed 15 years ago reported case fatality rates of 3.0%–3.5% (28,29). Due to the current 
laboratory surveillance system, we were able to quantify 30-day case-fatality rate of a reference 
group (CD unselected isolates not referred for typing) at 14%, which provides an updated 
estimate of such baseline category. In a registry-based study in Finland, performed before C. 
difficile PCR ribotype 027 was identified in the country for the first time, a 14.2% 30-day death 
rate was reported among those discharged with a CDAD-related diagnosis (30). In Quebec, 
13.8% of deaths reported 30 days after CDAD diagnosis were observed at the beginning of the 
C. difficile PCR ribotype 027 epidemic in 2003 (9). 
Many studies have reported that a consistent fraction of the deaths occurring after C. 
difficile infection will be attributable to the bacterium (1,8,12,21–23,31) and that attributable 
death increases linearly with age (8,31). In our study, we could not differentiate between death 
after infection and attributable death because the registries did not contain information on the 
cause of death nor underlying illness. An excess proportion of deaths caused by CD027 and other 
strains with binary toxin corroborates recent evidence from Canada, which showed an increased 
risk for death in patients infected with the NAP1 strain (24) 
Due to the availability of the national registries, we were able to investigate the case- 
fatality rate for a large cohort of patients and to get statistically significant results when 
investigating groups with different toxin profiles of the same infection. In addition, we 
performed multivariate analysis adjusting for age, sex, and region. Multivariate analysis 
indicated that the risk of death was increased by 60% (RR 1.6) for the strains possessing the 
binary toxin, irrespective of age, sex, and region of the laboratory submitting the isolates. Use of 
the registries made it possible to design the study on an individual patient basis, not only on 
isolates, and made it unlikely that deaths were missed. 
The main limitations of the study were that we were not able to collect data on underlying 
illness from the registries and that the toxin gene profile of the unselected isolates not referred 
for further typing was not characterized. We accounted for the latter possible bias by excluding 
this group in the regression analysis, and by using the group toxin profiled without genes for Page 9 of 15 
binary toxin (CD A and B) as the reference level. The lack of availability of data on underlying 
illness means that the long-term case fatality explored with the Kaplan Meier survival function 
must be interpreted with caution. However, our estimates at 3 months after infection were 
comparable to those of a previous study in which confounding caused by underlying illness was 
addressed (12). Therefore, C. difficile could play a role in risk for death in the longer term. An 
increase in long-term deaths after bacterial gastrointestinal infections has been observed (32,33). 
Complications of operations performed after toxic megacolon, disruption of the colonic flora and 
intestinal cells, subsequent malabsorbtion, and, most importantly, the recurrence of infection, 
could be some of the mechanisms involved in long-term deaths after infection with C. difficile. 
About 19%–20% of first episodes of infection with C. difficile will be followed by a recurrence 
(34), either due to a relapse or reinfection with another strain. 
In conclusion, our registry-based study demonstrates that patients infected with C. 
difficile strains possessing the binary toxin genes and genes encoding toxins A and B have a 
higher 30-day case-fatality rate, irrespective of PCR ribotype, when compared with strains that 
have toxins A and B only. Early recognition of the toxin profile might be beneficial in terms of 
clinical management of the disease. Future studies should address whether the binary toxin or an 
unknown co-expressed factor might be responsible for increased case-fatality rates. C. difficile 
PCR ribotype 027 can no longer be considered the only PCR ribotype associated with severe 
disease, and efforts to control CDI should target all virulent strains of C. difficile, not only C. 
difficile PCR ribotype 027.    
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Table 1. Characteristics of case-patients according to group of Clostridium difficile infection, week 1, 2008–week 22, 2009, Denmark 
Characteristic 
No binary toxin 
 
Presence of binary toxin  
No. (%) CD unselected, n = 1,822   No. (%) CD A and B, n = 212   No. (%) CD non-027, n = 72* 
Male sex  796 (43.7)  100 (47.2)    87 (45.1)  31 (43.1) 
Age group, y           
  <50  494 (27.1)  30 (14.2)    9 (4.6)  7 (9.7) 
  50–59  166 (9.1)  14 (6.6)    8 (4.1)  8 (11.1) 
  60–69   280 (15.4)  33 (15.6)    25 (13.0)  14 (19.4) 
  70–79  367 (20.1)  70 (33.0)    52 (26.9)  16 (22.2) 
  >80  514 (28.2)  65 (30.7)    99 (51.3)  27 (37.5) 
Region of local microbiology laboratory         
  Capital region  263 (14.4)  46 (21.7)    164 (85.0)  22 (30.5) 
  Other parts of Denmark  1,502 (83.4)  158 (74.4)    29 (15.0)  50 (69.4) 
*Consisting of C. difficile (CD) PCR ribotype 078 (n = 24), PCR ribotype 066 (n = 26), and PCR ribotype 023 and others (n = 22). 
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Table 2. Relative risk for death within 30 days after diagnosis of 
Clostridium difficile infection, univariate and multivariate analysis, 






Adjusted RR  
(95% CI) 
CD A and B  36  Reference  Reference 
CD 027 +  
CD non-027 
74  1.8 (1.2–2.7)  1.6 (1.01–2.4) 
Male sex  47  0.9 (0.6–1.2)  1.0 (0.7–1.4) 
Age group, y       
  <50  1  Reference  Reference 
  50–59  3  4.9 (0.5–47.2)  4.5 (0.5–43.9) 
  60–69  9  6.2 (0.8–48.8)  6.0 (0.8–47.3) 
  70–79  37  14.5 (2.0–105.8)  13.8 (1.9–100.9) 
  >80  60  17.4 (2.4–125.3)  15.5 (2.1–112.6) 
Region       
  Capital   63  1.4 (1.0–2.1)  0.9 (0.6–1.2) 
  Other parts  
  of Denmark 
47  Reference  Reference 
*RR, risk ratio; CI, confidence interval; CD, Clostridium difficile. 
 
 
Figure 1. Description of Clostridium difficile (CD) infections surveillance in Denmark, with the 4 groups of 
C. difficile–infected patients included in the study, week 1, 2008–week 22, 2009. SSI, Statens Serum 
Institut; R, resistance. Page 15 of 15 
 
Figure 2. Kaplan Meier curves showing the probability of patient survival after diagnosis of Clostridium 
difficile infection according to the 4 different infection groups (log-rank test, p<0.001). CD 027, C. difficile 
PCR ribotype 027; CD non-027, C. difficile PCR ribotype non-027; CD A and B, C.difficile with toxins A 
and B without binary toxin; CD unselected, C. difficile unselected strains not referred for typing. 
 
 